HCC1806(人乳腺癌细胞)
CBP60373
询 价
索取STR
产品描述
产品数据库
I. General information | |
Synonyms: | HCC1806 |
Background: | The HCC1806 breast cancer cell line was initiated on July 31, 1995, and took 10 months to establish. |
Species: | Homo sapiens, human |
Tissue: | mammary gland; breast |
Disease: | TNM stage IIB, grade 2, primary acantholytic squamous cell carcinoma |
Gender: | female, 60 years, Black |
Morphology: | epithelial |
Growth Mode: | adherent, The line grows as attached medium-sized epithelial cells without floating cells. |
DNA Profile: | D5S818: 13 D13S317: 11 D7S820: 10, 12 D16S539: 10 vWA: 16, 18 TH01: 8 Amelogenin: X TPOX: 8, 9 CSF1PO: 12 Cobioer’s Cell Line Authentication Service |
Culture Medium: |
RPMI-1640+10%FBS HCC1806完全培养基,# CBP60373M |
Cryopreservation medium: | 90%FBS+10%DMSO |
Receptor Expression: | estrogen receptor, negative progesterone receptor, negative |
Oncogene: | her2/neu -, p53 - |
Genes Expressed: | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 |
Cellular Products: | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 |
Comments: | The tumor was classified as a TNM Stage IIB, grade 2, acantholytic squamous carcinoma with no lymph node metastasis. There was no family history of breast cancer. The cells are poorly differentiated. The cells are negative for expression of Her2-neu and for expression of p53. HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). The cells are homozygous for deletions in the FHIT gene at 3p14.2. For more information, please contact Cobioer (4008-750-250). |